VERTEX PHARMACEUTICALS INC (VX1.DE) Fundamental Analysis & Valuation

FRA:VX1 • US92532F1003

407.4 EUR
-7.6 (-1.83%)
Last: Mar 3, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This VX1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to VX1. VX1 was compared to 75 industry peers in the Biotechnology industry. VX1 gets an excellent profitability rating and is at the same time showing great financial health properties. VX1 has a decent growth rate and is not valued too expensively. These ratings would make VX1 suitable for quality investing!


Dividend Valuation Growth Profitability Health

7

1. VX1.DE Profitability Analysis

1.1 Basic Checks

  • VX1 had positive earnings in the past year.
  • VX1 had a positive operating cash flow in the past year.
  • VX1 had positive earnings in 4 of the past 5 years.
  • In multiple years VX1 reported negative operating cash flow during the last 5 years.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 14.78%, VX1 belongs to the top of the industry, outperforming 89.33% of the companies in the same industry.
  • VX1 has a Return On Equity of 21.22%. This is amongst the best in the industry. VX1 outperforms 92.00% of its industry peers.
  • With an excellent Return On Invested Capital value of 15.66%, VX1 belongs to the best of the industry, outperforming 93.33% of the companies in the same industry.
  • VX1 had an Average Return On Invested Capital over the past 3 years of 15.82%. This is above the industry average of 12.19%.
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROIC 15.67%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • VX1's Profit Margin of 31.35% is amongst the best of the industry. VX1 outperforms 88.00% of its industry peers.
  • VX1's Profit Margin has declined in the last couple of years.
  • The Operating Margin of VX1 (38.70%) is better than 92.00% of its industry peers.
  • In the last couple of years the Operating Margin of VX1 has declined.
  • VX1's Gross Margin of 86.28% is fine compared to the rest of the industry. VX1 outperforms 76.00% of its industry peers.
  • In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
Industry RankSector Rank
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. VX1.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so VX1 is creating value.
  • VX1 has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, VX1 has less shares outstanding
  • There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.8
WACC8.69%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.36 indicates that VX1 has no problem at all paying its short term obligations.
  • VX1 has a Current ratio (2.36) which is comparable to the rest of the industry.
  • VX1 has a Quick Ratio of 2.00. This is a normal value and indicates that VX1 is financially healthy and should not expect problems in meeting its short term obligations.
  • VX1 has a Quick ratio (2.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 2
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. VX1.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 6248.28% over the past year.
  • VX1 shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.27% yearly.
  • Looking at the last year, VX1 shows a quite strong growth in Revenue. The Revenue has grown by 8.90% in the last year.
  • VX1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.10% yearly.
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.80% on average over the next years. This is quite good.
  • Based on estimates for the next years, VX1 will show a quite strong growth in Revenue. The Revenue will grow by 9.17% on average per year.
EPS Next Y10.74%
EPS Next 2Y11.49%
EPS Next 3Y10.83%
EPS Next 5Y11.8%
Revenue Next Year9.09%
Revenue Next 2Y9.66%
Revenue Next 3Y10.22%
Revenue Next 5Y9.17%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

5

4. VX1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • VX1 is valuated quite expensively with a Price/Earnings ratio of 25.69.
  • VX1's Price/Earnings ratio is a bit cheaper when compared to the industry. VX1 is cheaper than 80.00% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.83. VX1 is around the same levels.
  • Based on the Price/Forward Earnings ratio of 23.19, the valuation of VX1 can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of VX1 indicates a rather cheap valuation: VX1 is cheaper than 82.67% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of VX1 to the average of the S&P500 Index (24.95), we can say VX1 is valued inline with the index average.
Industry RankSector Rank
PE 25.69
Fwd PE 23.19
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VX1 indicates a somewhat cheap valuation: VX1 is cheaper than 80.00% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, VX1 is valued cheaper than 84.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 35.95
EV/EBITDA 24
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of VX1 may justify a higher PE ratio.
PEG (NY)2.39
PEG (5Y)2.09
EPS Next 2Y11.49%
EPS Next 3Y10.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VX1.DE Dividend Analysis

5.1 Amount

  • No dividends for VX1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VX1.DE Fundamentals: All Metrics, Ratios and Statistics

VERTEX PHARMACEUTICALS INC

FRA:VX1 (3/3/2026, 7:00:00 PM)

407.4

-7.6 (-1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-04
Inst Owners97.56%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap103.37B
Revenue(TTM)12.00B
Net Income(TTM)3.68B
Analysts80
Price Target461.23 (13.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)6.21%
PT rev (3m)7.06%
EPS NQ rev (1m)-0.41%
EPS NQ rev (3m)-0.58%
EPS NY rev (1m)0.15%
EPS NY rev (3m)-1.34%
Revenue NQ rev (1m)-0.22%
Revenue NQ rev (3m)-0.15%
Revenue NY rev (1m)0.47%
Revenue NY rev (3m)-0.46%
Valuation
Industry RankSector Rank
PE 25.69
Fwd PE 23.19
P/S 10.23
P/FCF 35.95
P/OCF 32.27
P/B 6.93
P/tB 7.59
EV/EBITDA 24
EPS(TTM)15.86
EY3.89%
EPS(NY)17.57
Fwd EY4.31%
FCF(TTM)11.33
FCFY2.78%
OCF(TTM)12.63
OCFY3.1%
SpS39.81
BVpS58.81
TBVpS53.66
PEG (NY)2.39
PEG (5Y)2.09
Graham Number144.87
Profitability
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROCE 22.25%
ROIC 15.67%
ROICexc 22.65%
ROICexgc 25.38%
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
FCFM 28.47%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
ROICexc(3y)28.12%
ROICexc(5y)40.76%
ROICexgc(3y)34.64%
ROICexgc(5y)58.61%
ROCE(3y)22.47%
ROCE(5y)24.17%
ROICexgc growth 3Y-38.98%
ROICexgc growth 5Y-26.28%
ROICexc growth 3Y-31.44%
ROICexc growth 5Y-19.05%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 189.83%
Cap/Sales 3.25%
Interest Coverage 374.91
Cash Conversion 78.49%
Profit Quality 90.81%
Current Ratio 2.36
Quick Ratio 2
Altman-Z N/A
F-Score7
WACC8.69%
ROIC/WACC1.8
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
EPS Next Y10.74%
EPS Next 2Y11.49%
EPS Next 3Y10.83%
EPS Next 5Y11.8%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%
Revenue Next Year9.09%
Revenue Next 2Y9.66%
Revenue Next 3Y10.22%
Revenue Next 5Y9.17%
EBIT growth 1Y5.79%
EBIT growth 3Y1.84%
EBIT growth 5Y10.4%
EBIT Next Year6.57%
EBIT Next 3Y12.66%
EBIT Next 5Y11.86%
FCF growth 1Y346.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y541.25%
OCF growth 3YN/A
OCF growth 5YN/A

VERTEX PHARMACEUTICALS INC / VX1.DE FAQ

What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to VX1.DE.


What is the valuation status for VX1 stock?

ChartMill assigns a valuation rating of 5 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.


What is the profitability of VX1 stock?

VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.


How financially healthy is VERTEX PHARMACEUTICALS INC?

The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 7 / 10.


What is the earnings growth outlook for VERTEX PHARMACEUTICALS INC?

The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 10.74% in the next year.